Holen Sie sich die Stockscreener-App
16.74
0.78%
0.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga
Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - BioSpace
Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity - marketscreener.com
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News - GuruFocus
(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha
Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus
Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - BioSpace
Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com
Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus
BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Research Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World
B. Riley Brokers Boost Earnings Estimates for ARWR - Defense World
Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - Defense World
ARWR: Multiple Value Drivers for Long-Term Growth - Research Tree
Q3 Earnings Forecast for ARWR Issued By Leerink Partnrs - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum - MSN
ARWR July 18th Options Begin Trading - Nasdaq
ARWR: Multiple Value Drivers for Long-Term Growth… - Yahoo Finance
Citigroup Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $17.00 - Defense World
UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating - marketscreener.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript - Insider Monkey
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings Beat - Defense World
Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St - GuruFocus
RBC cuts Arrowhead Pharma target to $40; keeps Outperform By Investing.com - Investing.com Canada
Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News - GuruFocus
Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ - GuruFocus
Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR Stock News - GuruFocus
RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating - marketscreener.com
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... - Yahoo Finance
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highl - GuruFocus
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals (ARWR) Prepares for Commercial Launch - GuruFocus
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results - BioSpace
Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts - Investing.com Australia
Arrowhead Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings: EPS of $2 - GuruFocus
Arrowhead Pharmaceuticals Swings to Fiscal Q2 Earnings; Shares Rise After Hours - marketscreener.com
Arrowhead Pharmaceuticals soars 7% on massive earnings beat By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals soars 7% on massive earnings beat - Investing.com Australia
ARROWHEAD PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Arrowhead Pharmaceuticals (ARWR) Q2 Earnings Set for May 12 Rele - GuruFocus
0.00%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):